ArticleResearch square2026
Hybrid trial for Alcohol reduction among people with TB and HIV in India (HATHI): Protocol for a Hybrid Type 1 Effectiveness-Implementation Randomized Controlled Trial.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04230395 (Hybrid Trial for Alcohol Reduction Among People With TB and HIV in India), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Hybrid Trial for Alcohol Reduction Among People With TB and HIV in India (HATHI)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Background: The highest incidence of tuberculosis disease (TB) in the world is in India, accounting for 26% of all new cases globally, with approximately 48,000 among persons with HIV (PWH). Unhealthy alcohol use can worsen the health of people who have TB or HIV and those who have both TB and HIV. Behavioral interventions that target alcohol use and are integrated into TB and HIV care may lead to better outcomes. This paper describes the protocol for HATHI, Methods: HATHI is a randomized controlled trial that will recruit 450 people with unhealthy alcohol use from TB and HIV clinics in Pune, India. The aims of HATHI are to: (1) test if a four session behavioral intervention integrated into TB and HIV care results in lower alcohol use among persons with TB, HIV and TB/HIV coinfection compared to usual care as measured by phosphatidyl ethanol (PEth), an alcohol biomarker (primary outcome); (2) test if the same intervention also leads to improved TB and HIV clinical outcomes including TB and HIV medication adherence, HIV viral suppression, TB sputum/culture conversion and the composite outcome of TB treatment failure, default or death; (3) evaluate barriers and facilitators to integrating the intervention into TB and HIV care, and (4) determine the incremental costs of delivering the intervention in these clinical settings. We hypothesize that the HATHI intervention will result in lower alcohol use compared to standard of care use at 6 months among people and superior TB and HIV clinical outcomes at 12 months. Discussion: This intervention addresses unhealthy alcohol use, a known barrier to optimal TB and HIV treatment outcomes. If HATHI proves effective, insights into barriers and facilitators for integration will inform future scale-up of this behavioral alcohol intervention in TB and HIV clinical settings. Trial registration: ClinicalTrials.gov NCT04230395 (first submission 1/18/2020, most recently update 2/17/25) and India Clinical trial Registry CTRI/2020/03/024141.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.